Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Upgrade
South State upgraded to Outperform from Market Perform at Keefe Bruyette » 21:14
08/02/20
08/02
21:14
08/02/20
21:14
SSB

South State

$47.66 /

-0.04 (-0.08%)

Keefe Bruyette analyst…

Keefe Bruyette analyst Catherine Mealor upgraded South State to Outperform from Market Perform with a price target of $65, down from $70. The company's "strong" Q1 results with a better outlook for pre-provision net revenue earnings and increase in the allowance for credit losses to 1.96% provide for "significant credit cushion," better than expected tangible book value at deal close and a decrease in deferrals, Mealor tells investors in a research note. As such, the analyst sees South State as better positioned and 40% upside in the shares.

ShowHide Related Items >><<
SSB South State
$47.66 /

-0.04 (-0.08%)

07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
04/24/20 DA Davidson
South State upgraded to Buy from Neutral at DA Davidson
03/06/20 SunTrust
SunTrust cuts price targets on Banks amid lower interest rate environment
SSB South State
$47.66 /

-0.04 (-0.08%)

Saturday
On The Fly
Week in review: How Trump's policies moved stocks » 09:06
08/01/20
08/01
09:06
08/01/20
09:06
MSFT

Microsoft

$205.00 /

+1.135 (+0.56%)

, PFE

Pfizer

$38.48 /

-0.27 (-0.70%)

, AZN

AstraZeneca

$55.77 /

-2.13 (-3.68%)

, BMY

Bristol-Myers

$58.66 /

-0.22 (-0.37%)

, LLY

Eli Lilly

$150.24 /

-2.71 (-1.77%)

, GSK

GlaxoSmithKline

$40.31 /

+0.045 (+0.11%)

, JNJ

Johnson & Johnson

$145.78 /

-1.09 (-0.74%)

, MRK

Merck

$80.26 /

+1.21 (+1.53%)

, NVS

Novartis

$82.09 /

-2.115 (-2.51%)

, SNY

Sanofi

$52.43 /

-0.1 (-0.19%)

, MRNA

Moderna

$74.10 /

-3.5 (-4.51%)

, SNAP

Snap

$22.41 /

+ (+0.00%)

, TWTR

Twitter

$36.39 /

-0.34 (-0.93%)

, FB

Facebook

$253.82 /

+19.19 (+8.18%)

, GOOG

Alphabet

$1,482.46 /

-52.125 (-3.40%)

, GOOGL

Alphabet Class A

$1,487.69 /

-48.81 (-3.18%)

, AMZN

Amazon.com

$3,165.00 /

+114.03 (+3.74%)

, AAPL

Apple

$425.02 /

+39.88 (+10.35%)

, KODK

Eastman Kodak

$22.30 /

-7.53 (-25.24%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

Catch up on the top…

Open Full Text

ShowHide Related Items >><<
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

07/31/20 Stifel
Citrix disclosure points to $1B commitment, most likely to Azure, says Stifel
07/27/20 Morgan Stanley
Morgan Stanley downgrades Software industry view to In-Line from Attractive
07/23/20
Fly Intel: Top five analyst downgrades
07/23/20 Wedbush
Microsoft remains top cloud name at Wedbush
PFE Pfizer
$38.48 /

-0.27 (-0.70%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

07/31/20 Barclays
Barclays backs Overweight on AstraZeneca after Q2 results
07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

07/31/20 Barclays
Eli Lilly earnings selloff 'meaningful over-reaction,' says Barclays
07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

07/31/20 Barclays
Barclays backs Underweight on GSK after 'challenging' Q2
07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
MRK Merck
$80.26 /

+1.21 (+1.53%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
NVS Novartis
$82.09 /

-2.115 (-2.51%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
SNY Sanofi
$52.43 /

-0.1 (-0.19%)

07/31/20 JPMorgan
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan
07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
MRNA Moderna
$74.10 /

-3.5 (-4.51%)

07/27/20 Piper Sandler
Piper reiterates $134 Moderna target on start of Phase III vaccine trial
07/27/20 BMO Capital
Moderna price target lowered to $94 from $112 at BMO Capital
07/24/20 Baird
Arbutus Biopharma upside priced in, Baird downgrades to Neutral
SNAP Snap
$22.41 /

+ (+0.00%)

07/28/20 Morgan Stanley
Morgan Stanley lowers near-term, long-term forecasts for Roku
07/22/20
Fly Intel: Top five analyst downgrades
07/22/20 Oppenheimer
Snap price target raised to $28 from $18 at Oppenheimer
07/22/20 JPMorgan
Snap should be bought on any meaningful pullback, says JPMorgan
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

07/24/20 SunTrust
Twitter price target raised to $40 from $32 at SunTrust
07/24/20 Argus
Twitter price target raised to $46 from $40 at Argus
07/24/20 Canaccord
Twitter price target raised to $40 from $32 at Canaccord
FB Facebook
$253.82 /

+19.19 (+8.18%)

07/31/20
Facebook price target raised to $300 from $290 at JPMorgan
07/31/20 Wedbush
Facebook price target raised to $300 from $250 at Wedbush
07/31/20 RBC Capital
Facebook price target raised to $320 from $271 at RBC Capital
07/31/20 Raymond James
Facebook price target raised to $280 from $240 at Raymond James
GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

07/31/20
Fly Intel: Top five analyst downgrades
07/31/20 Guggenheim
Alphabet price target raised to $1,725 from $1,580 at Guggenheim
07/31/20 Raymond James
Alphabet price target raised to $1,700 from $1,425 at Raymond James
07/31/20 Oppenheimer
Alphabet price target raised to $1,685 from $1,445 at Oppenheimer
GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

07/31/20 RBC Capital
Alphabet price target raised to $1,700 from $1,500 at RBC Capital
07/31/20 Morgan Stanley
Alphabet price target raised to $1,760 from $1,700 at Morgan Stanley
07/31/20 Barclays
Alphabet price target raised to $1,800 from $1,600 at Barclays
AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

07/31/20 BMO Capital
Amazon.com price target raised to $3,700 from $3,500 at BMO Capital
07/31/20 RBC Capital
Amazon.com price target raised to $3,800 from $3,300 at RBC Capital
07/31/20 Guggenheim
Amazon.com price target raised to $3,600 from $2,700 at Guggenheim
07/31/20 Goldman Sachs
Amazon.com price target raised to $4,200 from $3,800 at Goldman Sachs
AAPL Apple
$425.02 /

+39.88 (+10.35%)

07/31/20 Canaccord
Canaccord boosts Apple target to $460 after 'impressive' quarter
07/31/20 RBC Capital
Apple price target raised to $445 from $390 at RBC Capital
07/31/20
Apple price target raised to $460 from $425 at JPMorgan
07/31/20 Loop Capital
Apple price target raised to $376 from $330 at Loop Capital
KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

  • 19
    May
  • 12
    Feb
TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

TWTR Twitter
$36.39 /

-0.34 (-0.93%)

SNY Sanofi
$52.43 /

-0.1 (-0.19%)

SNAP Snap
$22.41 /

+ (+0.00%)

PFE Pfizer
$38.48 /

-0.27 (-0.70%)

NVS Novartis
$82.09 /

-2.115 (-2.51%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

MRNA Moderna
$74.10 /

-3.5 (-4.51%)

MRK Merck
$80.26 /

+1.21 (+1.53%)

LLY Eli Lilly
$150.24 /

-2.71 (-1.77%)

KODK Eastman Kodak
$22.30 /

-7.53 (-25.24%)

JNJ Johnson & Johnson
$145.78 /

-1.09 (-0.74%)

GSK GlaxoSmithKline
$40.31 /

+0.045 (+0.11%)

GOOGL Alphabet Class A
$1,487.69 /

-48.81 (-3.18%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

FB Facebook
$253.82 /

+19.19 (+8.18%)

BMY Bristol-Myers
$58.66 /

-0.22 (-0.37%)

AZN AstraZeneca
$55.77 /

-2.13 (-3.68%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

AAPL Apple
$425.02 /

+39.88 (+10.35%)

MSFT Microsoft
$205.00 /

+1.135 (+0.56%)

GOOG Alphabet
$1,482.46 /

-52.125 (-3.40%)

AMZN Amazon.com
$3,165.00 /

+114.03 (+3.74%)

Friday
Recommendations
Sanofi price target raised to EUR 106 from EUR 103 at JPMorgan » 14:28
07/31/20
07/31
14:28
07/31/20
14:28
SNY

Sanofi

$51.91 /

-0.625 (-1.19%)

JPMorgan analyst Richard…

JPMorgan analyst Richard Vosser raised the firm's price target on Sanofi to EUR 106 from EUR 103 and keeps an Overweight rating on the shares.

ShowHide Related Items >><<
SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

SNY Sanofi
$51.91 /

-0.625 (-1.19%)

Initiation
Prosperity Bancshares initiated with a Peer Perform at Wolfe Research » 09:31
07/31/20
07/31
09:31
07/31/20
09:31
PB

Prosperity Bancshares

/

+

Wolfe Research analyst…

Wolfe Research analyst Bill Carcache initiated coverage of Prosperity Bancshares with a Peer Perform rating and $65 price target. Carcache has rolled out coverage of mid-cap regional banks at Market Underweight, saying his cautiousness on the group is based on their "anemic" top-line growth outlooks in a zero interest rate environment, though he does see some attractive relative value within the group. He started the consumer finance stock group at Market Overweight, based on his view that they will benefit from declining credit headwinds and "greater top-line torque" on the path to normalized earnings in 2022.

ShowHide Related Items >><<
PB Prosperity Bancshares
/

+

07/01/20 Piper Sandler
Prosperity Bancshares upgraded to Overweight from Neutral at Piper Sandler
06/09/20 Wedbush
Prosperity Bancshares downgraded to Neutral from Outperform at Wedbush
04/30/20 SunTrust
Prosperity Bancshares price target raised to $75 from $55 at SunTrust
04/30/20 BofA
Prosperity Bancshares upgraded to Neutral from Underperform at BofA
PB Prosperity Bancshares
/

+

PB Prosperity Bancshares
/

+

Hot Stocks
Sanofi, GSK selected for Operation Warp Speed to supply 100M doses of vaccine » 07:03
07/31/20
07/31
07:03
07/31/20
07:03
SNY

Sanofi

$52.53 /

-0.3 (-0.57%)

, GSK

GlaxoSmithKline

$40.26 /

-0.34 (-0.84%)

Sanofi (SNY) and GSK…

Sanofi (SNY) and GSK (GSK) announce a collaborative effort with the U.S. government to accelerate the development and manufacturing of a COVID-19 recombinant protein-based vaccine. The vaccine candidate, developed by Sanofi in partnership with GSK, is based on the recombinant protein-based technology used by Sanofi to produce an influenza vaccine, and GSK's established pandemic adjuvant technology. Collaborating with the U.S. Department of Health and Human Services and Department of Defense will help fund the development activities and secure scale-up of Sanofi's and GSK's manufacturing capabilities in the United States for the recombinant protein-based, adjuvanted vaccine, resulting in a significant increase in capacity. The U.S. government will provide up to $2.1B, more than half of which is to support further development of the vaccine, including clinical trials, with the remainder used for manufacturing scale-up and delivery of an initial 100 million doses of the vaccine. Sanofi will receive the majority of the U.S. government funding. The U.S. government has a further option for the supply of an additional 500 million doses longer term. This helps the U.S. government's Operation Warp Speed goals of providing millions of doses of a safe and effective COVID-19 vaccine. Sanofi is leading the clinical development and registration of the COVID-19 vaccine and expects a Phase 1/2 study to start in September, followed by a Phase 3 study by the end of 2020. If the data are positive, the companies can request U.S. regulatory approval in the first half of 2021. In parallel, Sanofi and GSK are scaling up manufacturing of the antigen and adjuvant to produce up to one billion doses per year globally.

ShowHide Related Items >><<
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

07/30/20 Roth Capital
Roth Capital bullish on Ideaya as GSK highlights synthetic lethality pipeline
07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

GSK GlaxoSmithKline
$40.26 /

-0.34 (-0.84%)

Hot Stocks
BioNTech announces strategic collaboration with Regeneron » 05:41
07/31/20
07/31
05:41
07/31/20
05:41
BNTX

BioNTech

$84.02 /

+1.6 (+1.94%)

, REGN

Regeneron

$630.81 /

-0.5 (-0.08%)

, SNY

Sanofi

$52.53 /

-0.3 (-0.57%)

BioNTech SE (BNTX)…

BioNTech SE (BNTX) announced a strategic collaboration with Regeneron (REGN) for a clinical trial combining BioNTech's BNT111 FixVac product candidate and Libtayo, a fully human anti-PD-1 therapy, for the treatment of melanoma. BioNTech said in a release, "The companies plan to jointly conduct a randomized Phase 2 study in patients with anti-PD1-refractory/relapsed, unresectable Stage III or IV cutaneous melanoma. Melanoma is the deadliest skin cancer and estimated to kill more than 63,000 people around the world this year. BNT111 is the most advanced of five clinical stage FixVac product candidates within BioNTech's broader development pipeline. It is an mRNA cancer immunotherapy targeting four antigens frequently expressed in the tumors of patients with melanoma - NY-ESO-1, MAGE-A3, tyrosinase, and TPTE. BNT111 has demonstrated clinical anti-tumor activity as a monotherapy and in combination with checkpoint inhibitors in an ongoing Phase 1 trial in patients with advanced melanoma after prior checkpoint blockade. The two companies plan to pursue a clinical trial for the combination in the second-line treatment setting for advanced melanoma. The companies plan to disclose more details related to the planned Phase 2 study in the third quarter of 2020, with the goal of initiating the trial in the fourth quarter of 2020. Under the terms of the agreement, development costs for the clinical trial will be shared equally and both companies will contribute their products for the trial. Each party will retain full commercial rights for its respective product and record revenues related to its own product. Libtayo is being jointly developed by Regeneron and Sanofi (SNY)."

ShowHide Related Items >><<
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

07/30/20 BofA
BofA says hard to compare Moderna COVID data to competing preclinical data
07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/21/20
Fly Intel: Top five analyst upgrades
07/21/20 Canaccord
BioNTech price target raised to $97 from $75 at Canaccord
REGN Regeneron
$630.81 /

-0.5 (-0.08%)

07/20/20 Credit Suisse
Regeneron price target raised to $716 from $700 at Credit Suisse
07/09/20
Fly Intel: Top five analyst upgrades
07/08/20 SunTrust
Regeneron upgraded to Buy at SunTrust on Eylea resilience and pipeline
07/08/20 SunTrust
Regeneron upgraded to Buy from Hold at SunTrust
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

  • 23
    Jul
  • 27
    May
  • 06
    Feb
  • 10
    Oct
SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

SNY Sanofi
$52.53 /

-0.3 (-0.57%)

REGN Regeneron
$630.81 /

-0.5 (-0.08%)

BNTX BioNTech
$84.02 /

+1.6 (+1.94%)

Thursday
Earnings
Hilltop Holdings reports Q2 cont ops EPS $1.08, consensus 49c » 17:46
07/30/20
07/30
17:46
07/30/20
17:46
HTH

Hilltop Holdings

$19.83 /

+0.465 (+2.40%)

Jeremy Ford, President…

Jeremy Ford, President and CEO of Hilltop, said, "While these remain very challenging times and there is significant uncertainty about the future impacts from the pandemic, I am very proud of our teammates across Hilltop as they continue to execute and display compassion for our clients and each other. Our results from the second quarter demonstrate the strength and durability of our operating model as the mortgage franchise delivered record pre-tax income of $138 million on $6 billion of mortgage originations, while the securities business grew pre-tax income by 26% to $28 million from strength in the fixed income capital markets and structured finance business lines. While the Bank incurred a pre-tax loss of $17 million, it generated pre-provision net revenue, or PPNR, of $48 million during the quarter driven by solid net interest income and lower operating expenses. The Bank also recognized approximately $66 million of provision expense related to significant deterioration in the economic outlook from the end of the first quarter through June. In addition to exceptional PPNR performance, we were also able to fortify our strong excess capital and liquidity positions during the quarter by executing a subordinated debt offering and closing the sale of National Lloyds."

ShowHide Related Items >><<
HTH Hilltop Holdings
$19.83 /

+0.465 (+2.40%)

HTH Hilltop Holdings
$19.83 /

+0.465 (+2.40%)

08/29/19 Raymond James
Hilltop Holdings upgraded to Outperform from Market Perform at Raymond James
HTH Hilltop Holdings
$19.83 /

+0.465 (+2.40%)

Earnings
South State reports Q2 adjusted EPS 89c, consensus 12c » 16:30
07/30/20
07/30
16:30
07/30/20
16:30
SSB

South State

$47.61 /

-1.27 (-2.60%)

"We are pleased to…

"We are pleased to have closed our merger of equals between South State and CenterState on June 7. While accounting rules under the recently-implemented CECL standard required us to book a large provision for credit loss expense on the closing of the merger, leading us to report a net loss for the quarter, I am very pleased with the underlying fundamental operating performance of the company," said CEO John Corbett. "53 days into our merger, we are off to a solid start," said Robert R. Hill, Jr., Executive Chairman. "We are building a sound, profitable, and growing company and I am pleased with our team's progress to date."

ShowHide Related Items >><<
SSB South State
$47.61 /

-1.27 (-2.60%)

07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
07/01/20 Raymond James
South State initiated with an Outperform at Raymond James
04/24/20 DA Davidson
South State upgraded to Buy from Neutral at DA Davidson
03/06/20 SunTrust
SunTrust cuts price targets on Banks amid lower interest rate environment
SSB South State
$47.61 /

-1.27 (-2.60%)

Conference/Events
Home Bancshares to hold a conference call » 13:25
07/30/20
07/30
13:25
07/30/20
13:25
HOMB

Home Bancshares

$16.56 /

-0.32 (-1.90%)

Management holds a…

Management holds a conference call featuring the Retail and Other Commercial Real Estate segments on July 30 at 2 pm. Webcast Link

ShowHide Related Items >><<
HOMB Home Bancshares
$16.56 /

-0.32 (-1.90%)

HOMB Home Bancshares
$16.56 /

-0.32 (-1.90%)

04/17/20 Raymond James
Home Bancshares upgraded to Outperform from Market Perform at Raymond James
04/17/20 Raymond James
Home Bancshares upgraded to Outperform from Market Perform at Raymond James
01/17/20 RBC Capital
Home Bancshares price target raised to $22 from $20 at RBC Capital
01/09/20 Citi
Home Bancshares downgraded to Neutral from Buy at Citi
HOMB Home Bancshares
$16.56 /

-0.32 (-1.90%)

Hot Stocks
Drug prices will soon be 'lowered massively' in U.S., Trump tweets » 09:51
07/30/20
07/30
09:51
07/30/20
09:51
JNJ

Johnson & Johnson

$147.11 /

+0.57 (+0.39%)

, LLY

Eli Lilly

$156.79 /

-5.03 (-3.11%)

, MRK

Merck

$78.20 /

-1.13 (-1.42%)

, PFE

Pfizer

$38.45 /

-0.06 (-0.16%)

, SNY

Sanofi

$51.85 /

-0.98 (-1.86%)

, AZN

AstraZeneca

$56.96 /

+0.39 (+0.69%)

, GSK

GlaxoSmithKline

$39.78 /

-0.82 (-2.02%)

, NVS

Novartis

$83.27 /

-1.08 (-1.28%)

, RHHBY

Roche

$0.00 /

+ (+0.00%)

, BMY

Bristol-Myers

$58.58 /

-0.58 (-0.98%)

President Donald Trump…

President Donald Trump tweeted: "Drug prices will soon be lowered massively. Big Pharma (Drug Companies) are advertising against me like crazy because lower prices mean less profit. When you watch a Fake Ad, just think lower drug prices!!!" Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

ShowHide Related Items >><<
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

07/29/20 Laidlaw
Curis initiated with a Buy at Laidlaw
07/17/20 Goldman Sachs
J&J valuation discount to S&P 500 'too wide,' says Goldman Sachs
07/17/20 Citi
Johnson & Johnson price target raised to $170 from $165 at Citi
07/16/20 Goldman Sachs
J&J delay to robotic surgery program a positive for Intuitive, says Goldman
LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

07/15/20 H.C. Wainwright
Blueprint Medicines price target raised to $110 from $66 at H.C. Wainwright
07/14/20 Baird
Blueprint Medicines price target raised to $100 from $90 at Baird
07/14/20 Raymond James
Blueprint Medicines price target raised to $106 from $95 at Raymond James
07/09/20 Morgan Stanley
Eli Lilly won't publish Phase 1 COVID antibody data, says Morgan Stanley
MRK Merck
$78.20 /

-1.13 (-1.42%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
PFE Pfizer
$38.45 /

-0.06 (-0.16%)

07/30/20 Morgan Stanley
Pfizer price target raised to $42 from $36 at Morgan Stanley
07/30/20 Mizuho
Pfizer price target raised to $43 from $38 at Mizuho
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

07/20/20 BMO Capital
Immunic initiated with an Outperform at BMO Capital
07/08/20 Piper Sandler
Piper upgrades Kiadis on 'platform validating' Sanofi deal
07/06/20 Citi
BioMarin price target raised to $148 from $105 at Citi
07/01/20 Roth Capital
Applied Genetic may attract Sanofi takeover interest, says Roth Capital
AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

07/29/20 Barclays
AstraZeneca price target raised to 9,300 GBp from 9,200 GBp at Barclays
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
06/24/20 Oddo BHF
AstraZeneca downgraded to Reduce from Buy at Oddo BHF
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

07/13/20 UBS
UBS reiterates Buy on GSK as FDA belantamab docs are out
07/13/20 JPMorgan
Ideaya upgraded to Overweight on recent pullback at JPMorgan
06/19/20 Barclays
Glaxo belantamab AdCom a surprise, supports cautious view, says Barclays
NVS Novartis
$83.27 /

-1.08 (-1.28%)

07/28/20 Morgan Stanley
Novartis price target raised to CHF 93 from CHF 91 at Morgan Stanley
07/01/20 Piper Sandler
Amgen appeal rules in favor of patent validity, says Piper Sandler
07/01/20 Jefferies
Amgen win on Enbrel patent removes key overhang, says Jefferies
07/01/20 Goldman Sachs
Global Blood Therapeutics upgraded to Buy from Neutral at Goldman Sachs
RHHBY Roche
$0.00 /

+ (+0.00%)

07/29/20 UBS
Roche price target raised to CHF 390 from CHF 380 at UBS
07/29/20 Morgan Stanley
Roche price target raised to CHF 375 from CHF 370 at Morgan Stanley
07/24/20 Credit Suisse
Credit Suisse backs Neutral on Roche after H1 results
07/24/20 UBS
Roche Q2 sales weak but recovery in June is evident, says UBS
BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

07/28/20 Mizuho
Wait for Bristol-Myers' bb2121 submission making some 'nervous,' says Mizuho
07/28/20
Fly Intel: Top five analyst initiations
07/28/20 Raymond James
Bristol-Myers initiated with an Outperform at Raymond James
07/22/20 Morgan Stanley
Morgan Stanley sees 'encouraging news' coming in near-term for Bristol-Myers
SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

RHHBY Roche
$0.00 /

+ (+0.00%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

SNY Sanofi
$51.85 /

-0.98 (-1.86%)

PFE Pfizer
$38.45 /

-0.06 (-0.16%)

NVS Novartis
$83.27 /

-1.08 (-1.28%)

MRK Merck
$78.20 /

-1.13 (-1.42%)

LLY Eli Lilly
$156.79 /

-5.03 (-3.11%)

JNJ Johnson & Johnson
$147.11 /

+0.57 (+0.39%)

GSK GlaxoSmithKline
$39.78 /

-0.82 (-2.02%)

BMY Bristol-Myers
$58.58 /

-0.58 (-0.98%)

AZN AstraZeneca
$56.96 /

+0.39 (+0.69%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.